Benzinga··Globe NewswireEton Pharmaceuticals Bolsters Rare Disease Portfolio With HEMANGEOL Acquisition
Eton Pharmaceuticals acquires HEMANGEOL commercialization rights, the only FDA-approved infantile hemangioma treatment, expanding its portfolio to ten commercial products with 2026 earnings accretion expected.
ETONrare diseaseorphan drug